Medicinal Cannabis Matters – Friday Roundup 1st August 2025
This week saw a major clinical breakthrough for migraine treatment and an exciting new chapter for Medicann as it expands access to patients across the UK.
New Study: Cannabis Relieves Migraines
A major clinical trial from UC San Diego has confirmed that vapourised cannabis (6% THC + 11% CBD) offers fast and lasting relief for migraine sufferers:
- 67% had pain relief within 2 hours
- 34% were completely pain-free
- Effects lasted up to 48 hours
- Minimal side effects reported
This is the first placebo-controlled study to show cannabis can be effective for acute migraine attacks.
If you or someone you know is suffering with migraines, get in touch with our experienced medicinal cannabis prescribing experts for a consultation.
Read the full study summary via Forbes
Medicann Expands to the UK
Medicann has officially launched its virtual clinic and e-pharmacy across England, Wales, Scotland, and Northern Ireland — offering patients faster, more convenient access to regulated cannabis-based care.
With over 50 eligible conditions, including anxiety, chronic pain, PTSD, fibromyalgia, and neurological disorders, Medicann’s remote service puts personalised treatment within reach.
Dr Sunny Nayee, Medical Director, says the focus is on “clinical integrity, convenience, and compassionate care.”
Learn more and check your eligibility at medicann.co.uk
Thank you for reading — we’ll be back next Friday with more updates from the world of medicinal cannabis.